Amanta Healthcare Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
AMANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amanta Healthcare has submitted its quarterly statement confirming no deviation in the use of IPO proceeds raised in September 2025 (₹126 crore). Of the ₹7,000 lakh allocated for the SteriPort manufacturing line at Hariyala, Kheda, ₹3,080.86 lakh has been utilized. The SVP manufacturing line (₹3,013.11 lakh allocated) remains undeployed. Issue expenses exceeded estimates by ₹358.38 lakh, which was offset by reducing General Corporate Purpose allocation from ₹660.46 lakh to ₹302.08 lakh. Both the Audit Committee and auditors have given no comments, indicating standard review with no concerns flagged.
No immediate shareholder concern — the company confirms fund utilization is aligned with stated objects. Pending deployment of ₹3,013 lakh for SVP line warrants monitoring in future quarters.